Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Isofol in conjunction with capital procurement
Mandate

Vinge advises Isofol in conjunction with capital procurement

April 02, 2020 Capital Markets and Public M&A Corporate Tax

Vinge has advised Isofol Medical AB (publ), First North Growth Market Premier, in connection with its rights issue in the total amount of MSEK 150 and, conditional upon oversubscription in respect of the rights issue, a directed new issue of shares of a total amount of MSEK 30.

Isofol has convened an extraordinary general meeting which is proposed to grant authority to the board of directors to adopt resolutions concerning the new issues of shares. The rights issue is fully   underwritten through underwriting undertakings and guarantee obligations.

Vinge’s team primarily consisted of Anders Strid, Wibeke Sorling, Jenny Sandlund (all Capital Markets) as well as Victor Ericsson and Emelie Svanberg (Tax).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025